Therapy Areas: Vaccines
Keyhole Limpet Hemocyanin Study Reveals Consistency of Molecular Structure Maintained in Production
26 June 2018 - - Port Hueneme, California-based biotech company Stellar Biotechnologies, Inc. (NASDAQ: SBOT) has completed a research study focused on the molecular composition of Stellar's keyhole limpet hemocyanin (KLH) products, the company said.
As part of the study, third party researchers analysed the patterns of carbohydrates that attach to the KLH protein through a biologic process known as glycosylation.
The compositional profile of these glycans are believed to enhance the immunogenicity of KLH.
Due in part to the large size and complexity of this glycosylation, KLH has never been synthesized.
To produce KLH, hemocyanin protein is extracted from its native source using Stellar's patented process and then purified and manufactured into various grades and formulations.
Stellar executive vice president of corporate development, Gregory T. Baxter, PhD reported that study results demonstrated highly consistent molecular structure from batch to batch, a key attribute for a biologically sourced protein, and that the greater insight into the characteristics of the KLH molecule revealed in the study may be useful in better understanding conjugation efficiency, a metric important to therapeutic vaccine developers.
Login
Username:

Password: